Development of a Direct-to-Biology Platform to Discover Potent MNK Inhibitors
values as low as 23 nM in LN229 cells. This work establishes a D2B approach as an effective strategy for efficient kinase inhibitor optimization.
Authors
- Leonidas C. Platanias (ORCID: https://orcid.org/0000-0002-9740-7573)
- Yingyu Mao (ORCID: https://orcid.org/0000-0001-5182-7401)
- Purav P. Vagadia
- Frank Eckerdt
- Joshua L. Zhu
- Gary E. Schiltz (ORCID: https://orcid.org/0000-0003-4180-5051)
Institutions
- Jesse Brown VA Medical Center (US)
- High Throughput Biology (United States) (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-05-13
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c00368
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- State of Illinois
- International Institute for Nanotechnology, Northwestern University
- NIH Office of the Director
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- Division of Electrical, Communications and Cyber Systems